UniQure Shares Rise After US FDA Grants Regenerative Medicine Advanced Designation for Huntington's Treatment

uniQure (QURE) shares rose 8% in recent Monday trading after the company obtained the regenerative medicine advanced therapy designation from the US Food and Drug Administration for AMT-130 to treat H

MT NewswiresJun 3 10:59 ET

UniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington's Disease

~ Designation based on 24-month interim Phase I/II clinical data for AMT-130 announced in December 2023 ~ ~ AMT-130 is the first therapeutic candidate to receive RMAT Designation for Huntington's disease ~ ~ Receiving

GlobeNewswireJun 3 07:05 ET

UniQure N.V. (NASDAQ:QURE) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

It's been a good week for uniQure N.V. (NASDAQ:QURE) shareholders, because the company has just released its latest quarterly results, and the shares gained 4.5% to US$4.89. Revenues of US$8.5m

Simply Wall StMay 9 06:16 ET

Stifel Nicolaus Sticks to Its Buy Rating for UniQure (QURE)

TipRanksMay 8 22:10 ET

UniQure Price Target Maintained With a $25.00/Share by HC Wainwright & Co.

UniQure Price Target Maintained With a $25.00/Share by HC Wainwright & Co.

Dow JonesMay 8 15:17 ET

Express News | HC Wainwright & Co. Reiterates Buy on UniQure, Maintains $25 Price Target

BenzingaMay 8 15:07 ET